Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
177
-
Total 13F shares, excl. options
-
119M
-
Shares change
-
+13.5M
-
Total reported value, excl. options
-
$1.56B
-
Value change
-
+$135M
-
Put/Call ratio
-
1.29
-
Number of buys
-
116
-
Number of sells
-
-81
-
Price
-
$13.11
Significant Holders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) as of Q2 2025
242 filings reported holding EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) has 177 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 119M shares
.
Largest 10 shareholders include ORBIMED ADVISORS LLC (15.5M shares), RA CAPITAL MANAGEMENT, L.P. (9.9M shares), BAKER BROS. ADVISORS LP (7.31M shares), BlackRock, Inc. (6.78M shares), Paradigm Biocapital Advisors LP (6.14M shares), JANUS HENDERSON GROUP PLC (5.5M shares), NOVO HOLDINGS A/S (5.35M shares), BRAIDWELL LP (5.21M shares), VANGUARD GROUP INC (4.84M shares), and PERCEPTIVE ADVISORS LLC (4.64M shares).
This table shows the top 177 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.